The Week in Bio #34
Research highlights from the week
Resolution of a human super-enhancer by targeted genome randomisation (link). Preprint describing the randomisation of the OTX2 super-enhancer to understand its regulatory architecture.
Rapid discovery of cyclic peptide protein aggregation inhibitors by continuous selection (link). Paper that uses phage-assisted continuous evolution (PACE) for selecting cyclic peptide protein aggregation inhibitors.
Outlook for medicines development and use in 2025 (link). Commentary on oncology innovation, obesity medicines, the M&A landscape and AI applications in drug discovery.
De novo designed proteins neutralize lethal snake venom toxins (link). Paper using deep learning methods to design neurotoxin binders.
Biopharma dealmaking in 2024 (link). Commentary on M&A and partnerships in 2024.
Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs (link). New preprint from Lycia Therapeutics describing cataLYTACs for degrading circulating protein targets.
Regulation of protein abundance in normal human tissues (link). Preprint describing a proteomic dataset measuring 10,000 proteins across five tissues.
In vivo base editing extends lifespan of a humanized mouse model of prion disease (link). Paper describing the treatment of a prion disease mouse model with base editors.